- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01914900
Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients with stage T2 (> 3 cm) T3 N1-N3 and T4a any N primary OCSCC are considered for enrolment in this trial. Patients will be asked to sign the informed consent for being admitted to the clinical study and in order to analyze the tumour biopsy. If a functional p53 protein status and/or low expression of beta-tubulin II is identified, patient will be enrolled in therapeutic part of the study. In case of different molecular profile, patient will not be enrolled in the study. A radiological work up of disease is required before to start CT. A magnetic resonance imaging (MRI) with DWI, and if available, a dynamic contrast enhanced (DCE)-MRI will be performed before therapy.
Each patient will receive induction CT, consisting of TPF (docetaxel 75 mg/sm and cisplatin 80 mg/sm day 1 and 5 fluorouracil 800 mg/sm each day in continuous infusion day 1-4, according to Paccagnella et al, ASCO 2008) for 3 cycles every 21 days, followed by surgery. Prophylactic antibiotic with ciprofloxacin 500 mg 2 times/day will be administered starting from day 5th to day 15th after each cycle; G-CSF is admitted as secondary prophylaxis in case of febrile neutropenia or neutropenia grade 4 at previous cycle. Patient will have clinical examination at baseline and before each CT cycle. Whenever a clinical suspicion of progressing disease will exist, a radiological restaging with MRI will be performed and in case of radiological progression according to RECIST 1.1 the patient will be submitted to surgical excision of the tumour. However, in any case the investigators may 14 judge that the disease is progressing and they consider that chemotherapy is no more indicated, the patient will be submitted to surgery even without a radiological confirmation of progression. In case of clinical SD or PR, a radiological restaging will be planned with MRI and DWI-MRI at least two weeks after the third cycle (a DWI- MRI and, if available a DCE-MRI, will be performed after 1st cycle in order to evaluate early response imaging). Surgery will be performed within one month after the last cycle of CT, if there are no clinical contraindications. After the surgical treatment, adjuvant treatment will be delivered according to recognized pathological risk factors (Bernier J, 2005). Patients will be followed up according to the Institutional follow-up policy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Milano, Italy, 20133
- Istituto Nazionale Tumori
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent
- Males and females age > 18 years
- Histologically proved primary oral cavity squamous cell cancer (tumour extending to oropharynx are accepted if oropharyngeal invasion is < 20% of the tumour size)
- Stage T2 (T2 stage is accepted if tumour size is 3 cm or larger).-T3, N1- N3 and T4a any N
- WHO performance status < 1
- Availability of block of Formalin Fixed Paraffin Embedded (FFPE) biopsy of the tumour
- Radiological imaging of the tumour with MRI pre-therapy
- Effective contraception for both male and female subjects if risk of conception exists
Exclusion Criteria:
- Prior antitumour therapy for head & neck cancer (chemotherapy or biological therapy and radiotherapy)
- Metastatic disease
Medical condition that contraindicate administration of TPF scheme, in particular:
- clinically significant cardiac disease including unstable angina, acute myocardial infarction in the previous 2 years, congestive heart failure and arrhythmia requiring therapy
- chronic or current infectious disease that contraindicate administration of chemotherapy causing neutropenia; known HIV, Hepatitis B or C positivity
- uncontrolled renal, hepatic, neurological, cerebral, psychiatric, haematological, gastrointestinal, pulmonary, vascular or endocrine diseases that could interfere with antiblastic treatment
- Pre-existing peripheral neuropathy according to Common Toxicity Criteria (CTC) Adverse Event grade > 1
- Pre-existing ototoxicity grade > 1
- Previous diagnosis of other cancer in the last 3 years (in situ cervical cancer or completely excised basocellular/squamocellular skin cancer are always admitted )
- Previous other cancer in oral cavity to less than 2 cm from existing primary
- Breast feeding women or women with a positive pregnancy test at Visit 0 or 1
Screening laboratory values:
- Neutrophils < 1.5 x 109/L
- Platelets < 100 x 109/L
- ALT or AST > 2.5 times upper limit of normal
- Calculated creatinine clearance < 60 mL/min
- Weight loss more than 20% in 3 months preceding the study
- Technical unresectability defined as: T4b staging or N ulcerating the skin or encasing internal carotid
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: induction TPF chemotherapy
Each patient will receive induction CT, consisting of TPF (docetaxel 75 mg/sm and cisplatin 80 mg/sm day 1 and 5 fluorouracil 800 mg/sm each day in continuous infusion day 1-4, according to Paccagnella et al, ASCO 2008) for 3 cycles every 21 days, followed by surgery.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pathologic complete remission
Time Frame: After 9 weeks since chemotherapy start
|
For what concerns primary endpoint of pathologic complete remission achievement, the patients will be assessed at time of surgery, i.e., after about 9 weeks since chemotherapy start.
|
After 9 weeks since chemotherapy start
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: 5 years
|
Patients will be followed up to 5 years for what concerns PFS
|
5 years
|
Overall Survival
Time Frame: 5 years
|
Patients will be followed up to 5 years for what concerns OS
|
5 years
|
Early functional response evaluation by DWI and DCE MRI
Time Frame: 3 weeks
|
radiological evaluation after 1 cycle of induction chemotherapy
|
3 weeks
|
Comparison between (DWI - DCE) MRI response and pathological response
Time Frame: 9 weeks
|
comparison between radiological assessment of response and pathological one
|
9 weeks
|
Compliance to induction chemotherapy
Time Frame: 9 weeks
|
Evaluation in terms of the number of cycles administered, actual and total doses dministered, dose modifications, delays and omissions, as well as reasons for deviation from planned therapy and overall treatment duration will be described
|
9 weeks
|
Percentage of patient receiving postoperative radiotherapy and chemotherapy
Time Frame: 6 months
|
Patients will be followed for what concerns PFS, defined as the time from the date of randomization up to the date of first progression, second primary malignancy or death from any cause, whichever comes first.
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lisa Licitra, MD, Fondazione IRCCS Istituto Nazionale dei tumori - Milan
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Carcinoma, Squamous Cell
- Neoplasms, Squamous Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
- Cisplatin
- Fluorouracil
Other Study ID Numbers
- INT40/10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
-
National Cancer Institute (NCI)RecruitingClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVA Lip and Oral... and other conditionsUnited States, Canada
-
University of WashingtonBlaze Bioscience Inc.RecruitingStage III Lip and Oral Cavity Cancer AJCC v8 | Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Stage IVA Lip and Oral Cavity Cancer AJCC v8United States
-
Ohio State University Comprehensive Cancer CenterCompletedTongue Cancer | Lip and Oral Cavity Squamous Cell Carcinoma | Oral Cavity Verrucous Carcinoma | Stage 0 Lip and Oral Cavity CancerUnited States
-
University Health Network, TorontoAstraZeneca; Mirati Therapeutics Inc.WithdrawnSquamous Cell Carcinoma, Head And Neck | Squamous Cell Carcinoma Mouth | Resectable Squamous Cell Carcinoma of Oral CavityCanada
-
National Cancer Institute (NCI)NRG OncologyRecruitingClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVA Lip and Oral... and other conditionsUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingOral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Buccal Mucosa Squamous Cell Carcinoma | Floor of Mouth Squamous Cell Carcinoma | Gingival Squamous Cell Carcinoma | Hard Palate Squamous Cell Carcinoma | Lip Squamous Cell... and other conditionsUnited States, Canada
-
Hyunseok Kang, MDNRG OncologyCompletedClinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IV Hypopharyngeal... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingRecurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Pharyngeal Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma of Unknown Primary | Resectable Head and Neck Squamous Cell CarcinomaUnited States
-
Emory UniversityBristol-Myers Squibb; Brooklyn ImmunoTherapeutics, LLCWithdrawnStage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | Stage II Oral Cavity Squamous Cell...United States
-
Shanghai Jiao Tong University School of MedicineCompletedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage III Oral Cavity Squamous Cell CarcinomaChina
Clinical Trials on docetaxel, cisplatin, 5 fluorouracil
-
Zhejiang Cancer HospitalWenzhou Medical University; Second Affiliated Hospital, School of Medicine,... and other collaboratorsUnknownNasopharyngeal Carcinoma | ChemoradiationChina
-
SanofiCompletedHead and Neck Neoplasms | Neoplasm Metastasis | Neoplasm Recurrence, LocalRussian Federation, United States, Canada, Germany, Hungary, Italy, South Africa, Argentina, Uruguay, Austria, Switzerland, Israel, Belgium, France, Australia, Brazil, Greece, Guadeloupe, Réunion, Spain
-
Southwest Oncology GroupNational Cancer Institute (NCI)TerminatedHead and Neck CancerUnited States
-
Centre Hospitalier Universitaire de BesanconCompletedAnal Canal CarcinomaFrance
-
Sun Yat-sen UniversityRecruitingNasopharyngeal Carcinoma | Circulating Tumor Cell | Effects of Chemotherapy | Distant Metastases.ClinicalChina
-
Gruppo Oncologico del Nord-OvestUnknownSquamous Cell Carcinoma of the Head and NeckItaly
-
Institute of Oncology LjubljanaCompletedHead and Neck CancerSlovenia
-
Orlando Guntinas-Lichius, Prof. Dr. med.CompletedOropharynx Cancer | Squamous Cell Carcinoma of the Oral CavityGermany